Phase 2Terminated

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Sponsor
Processa Pharmaceuticals (Industry)
Enrollment
20 enrolled
Conditions
Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer
Interventions
PCS6422 and capecitabine; Capecitabine
Ages
adults, older adults
Registry
NCT06568692

Full record on ClinicalTrials.gov

From the registry

This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors.

Primary outcomes

  • Evaluation of Objective Response Rate (ORR)
  • Number of patients with adverse events (AEs)

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered